Milrinone improves diastolic function in coronary artery bypass surgery as assessed by acoustic quantification and peak filling rate: a prospective randomized study.
OBJECTIVE
To compare the effects of a bolus dose of milrinone, 50 microg/kg, to placebo on diastolic function (active relaxation) in patients undergoing on-pump coronary artery bypass grafting (CABG).


METHODS
Prospective, randomized, double-blind, placebo-controlled study.


METHODS
University hospital.


METHODS
Twenty-four patients with stable angina and left ventricular ejection fraction >30%, scheduled for elective CABG using cardiopulmonary bypass (CPB), were included.


METHODS
Patients were randomized to receive either 50 microg/kg of milrinone (n = 12) or placebo (n = 12) after aortic declamping.


RESULTS
The diastolic function of the left ventricle (LV) was measured as peak filling rate (dA/dt [maximal diastolic area change over time]) with transesophageal echocardiography (TEE) using acoustic quantification (AQ) before CPB and 10 minutes after termination of CPB. The normalized peak filling rate (dA/dt)/EDA was also calculated. Active relaxation was statistically significantly increased in the milrinone group compared with the placebo group after CPB.


CONCLUSIONS
Patients undergoing CABG surgery and treated with milrinone after aortic declamping had better diastolic function following cardiopulmonary bypass.
Axelsson
Birger
B
Department of Cardiothoracic Surgery and Anesthesiology, Orebro University Hospital, Orebro, Sweden. birger.axelsson@orebroll.se
Arbeus
Mikael
M
Magnuson
Anders
A
Hultman
Jan
J
D000162:Acoustics; D000368:Aged; D001026:Coronary Artery Bypass / Q000009:adverse effects; D003971:Diastole / Q000187:drug effects* / Q000502:physiology*; D004311:Double-Blind Method; D017548:Echocardiography, Transesophageal / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020105:Milrinone / Q000494:pharmacology* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000175:diagnosis / Q000517:prevention & control; D011446:Prospective Studies; D016896:Treatment Outcome
D020105:Milrinone